Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole

Breast

Volumn 17, Issue 6, 2008, Pages 631-636

  Valenzano Menada, Mario ^a   Costantini, Sergio ^a   Moioli, Melita ^a   Bogliolo, Stefano ^a   Papadia, Andrea ^a   Ferrero, Simone ^a   Dugnani, Maria Cristina ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Adjuvant treatment; Anastrozole; Breast cancer; Endometrial pathology; Endometrial thickness; Tamoxifen; Transvaginal ultrasonography

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIAL DISEASE; FEMALE; HUMAN; HYSTEROSCOPY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY; TREATMENT DURATION;

EID: 56649124725     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.05.008     Document Type: Article

References (40)

1. Fisher B., Costantino J.P., Wickerham D.L., et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86 (1994) 527-537
2. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
3. Magriples U., Naftolin F., Schwartz P.E., et al. High-grade endometrial carcinoma in tamoxifen treated breast cancer patients. J Clin Oncol 11 (1993) 485-490
4. Curtis R.E., Boice Jr. J.D., Shriner D.A., et al. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88 (1996) 832-834
5. Stearns V., and Gelmann E.P. Does tamoxifen cause cancer in humans?. J Clin Oncol 16 (1998) 779-792
6. Van Leeuwen F.E., Benraadt J., Coeberg J.W.W., et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343 (1994) 448-452
7. Seoud M., Shamseddine A., Khalil A., et al. Tamoxifen and endometrial pathologies: a prospective study. Gynecol Oncol 75 (1999) 15-19
8. Fornander T., Rutqvist L.E., Cedermark B., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 (1989) 117-120
9. Rutqvist L.E., Johansson H., Signomklao T., et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87 (1995) 645-651
10. Bergeron C. Effects of estrogens and antiestrogens on the endometrium. Gynecol Obstet Fertil 30 (2002) 93
11. Kedar R.P., Bourne T.H., Powels T.J., et al. Effect of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343 (1994) 1318-1321
12. Smith I.E. Recent advances in the treatment of breast cancer. Breast 13 (2004) S1-S2
13. Smith I.E. Aromatase inhibitors - extending the benefits of adjuvant therapy beyond tamoxifen. Breast 13 (2004) S3-S9
14. Hann L.E., Giess C.S., Bach A.M., et al. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. Am J Roentgenol 168 (1997) 657-661
15. Gerber B., Krause A., Muller H., et al. Effects of adjuvant tamoxifen on the endometrium in post menopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 23 (2005) 619-629
16. Bertelli G.F., Valenzano M., Costantini S., et al. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. Gynecol Oncol 78 (2000) 275-277
17. Ismail S.M. The effects of tamoxifen on the uterus. Curr Op Obstet Gynecol 8 (1996) 27-31
18. Bertelli G., Venturini M., Del Mastro L., et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 47 1 (1998 Jan) 41-46
19. Fung M.F., Reid A., Faught W., et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 91 1 (2003 Oct) 154-159
20. Garuti G., Cellani F., and Grossi F. Saline infusion sonography and office hysteroscopy to assess Endometrial morbidity associated with tamoxifen intake. Gynecol Oncol 86 (2002) 323-329
21. Develioglu O.H., Omak M., and Bilgin T. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow. Gynecol Oncol 93 (2004) 328-335
22. Dowsett M., Jones A., Johnston S.R.D., et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1 (1995) 1511-1515
23. Geisler J., King N., Dowsett M., et al. Influence of anastrozole (Arimidex), a selective nonsteroidal aromatase inhibitor on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer. Br J Cancer 74 (1996) 1286-1291
24. ATAC Tials' Group. Results of the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
25. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23 (2005) 5138-5147
26. Early Breast Cancer Trialist's Collaborative Group (EBTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet 365 (2005) 1687-1717
27. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M., Arimidex, Tamoxifen, and Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 1 (2008 Jan) 45-53
28. Duffy S., Jackson T.L., Lansdown M., et al. The ATAC ('Arimidex' Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 21 (2006) 545-553
29. Garuti G., Cellani F., Centinaio G., et al. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. Gynecol Oncol 103 (2006) 599-603
30. Schmidt T., and Romer T. Sonography and hysteroscopy for endometrial carcinoma and its precursors. Zentralbl Gynakol 124 (2002) 20-26
31. Lindahl B., Andolf E., Ingvar C., et al. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen. Anticancer Res 17 (1997) 3821-3824
32. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
33. Morales L., Timmerman D., Neven P., et al. Third generation aromatase inhibitors may prevent and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 16 (2005) 70-74
34. Gerber B., Krause A., Reimer T., et al. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res. 12 (2006) 1245-1250
35. Garrone O., Mezi S., Occelli M., et al. Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients A prospective transvaginal ultrasound study (TVUS). Ann Oncol 14 Suppl 4 (2003) iv7 (Abstr A22)
36. Markovitch O., Tepper R., Fishman A., et al. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients. Breast Cancer Res Treat 101 2 (2007 Jan) 185-190
37. Valenzano Menada M., Papadia A., Lorenzi P., et al. Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. Eur J Gynaecol Oncol 25 (2004) 321-323
38. Cohen I., Beyth Y., Azzaria R., et al. Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients. Br J Obstet Gynecol 107 (2000) 1083
39. Love C.D., and Dixon J.M. Thickened endometrium caused by tamoxifen returns to normal following tamoxifen cessation. Breast 9 (2000) 156-157
40. Agorastos T., Vaitsi V., Pantazis K., et al. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 118 (2005) 239-240